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Background: Prolonged PR interval (PRi) is associated with adverse outcomes. How-
ever, PRi determinants are poorly known. We aimed to identify the clinical determi-
nants of the PRi duration in the general population.
Hypothesis: Some clinical data are associated with prolonged PRi.
Methods: Cross-sectional study conducted between 2014 and 2017. Electrocardiogram-
derived PRi duration was categorized into normal or prolonged (>200 ms). Determinants
were identified using stepwise logistic regression, and results were expressed as
multivariable-adjusted odds ratio (OR) (95% confidence interval). A further analysis was
performed adjusting for antiarrhythmic drugs, P-wave contribution to PRi duration, elec-
trolytes (kalemia, calcemia, and magnesemia), and history of cardiovascular disease.
Results: Overall, 3655 participants with measurable PRi duration were included
(55.6% females; mean age 62 ± 10 years), and 330 (9.0%) had prolonged PRi. Step-
wise logistic regression identified male sex (OR 1.41 [1.02-1.97]); aging (65-74 years:
OR 2.29 [1.61-3.24], and ≥ 75 years: OR 4.21 [2.81-6.31]); increased height (per
5 cm, OR 1.15 [1.06-1.25]); hypertension (OR 1.37 [1.06-1.77]); and hs troponin T
(OR 1.67 [1.15-2.43]) as significantly and positively associated, and high resting heart
rate (≥70 beats/min, OR 0.43 [0.29-0.62]) as negatively associated with prolonged
PRi. After further adjustment, male sex, aging and increased height remained posi-
tively, and high resting heart rate negatively associated with prolonged PRi. Hyper-
tension and hs troponin T were no longer associated.
Conclusion: In a sample of the Swiss middle-aged population, male sex, aging and
increased height significantly increased the likelihood of a prolonged PRi duration,
whereas a high resting heart rate decreased it.
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1 | INTRODUCTION
The PR interval (PRi) on the electrocardiogram (ECG) measures the
conduction time from the beginning of the P-wave to the beginning
of the QRS complex. It reflects the conduction through the atria, atrio-
ventricular (AV) node, bundle and its branches, and Purkinje fibers.1
The normal values range between 120 and 200 millisecond and pro-
longed PRi or first-degree atrioventricular block are established when
the PRi is >200 millisecond. Prolonged PRi is a frequent ECG finding2
that has long been considered as harmless.3,4 Yet, one of the studies
defining prolonged PRi as benign was based on young and healthy
males4 and it has been hypothesized that elevated vagal tone and
decreased sympathetic tone lead to prolonged PRi, as found in well-
trained athletes.5 In 2009, Cheng et al. conducted a study in ambula-
tory individuals to assess the clinical significance of prolonged PRi.
They showed that prolonged PRi was associated with increased risk
of atrial fibrillation (AF), all-cause mortality, and pacemaker implanta-
tion.6 Consequently, other studies investigated the association
between prolonged PRi and several outcomes, including heart failure,
cardiovascular mortality or stroke.7-10 Contradictory findings were
found, some studies reporting a deleterious effect of prolonged PRi
on all-cause mortality,8,10 while others did not.7,9
The clinical determinants of prolonged PRi are mostly unknown.
Positive associations between the PRi and greater age,7,10 BMI,7,11 or
genetic markers12 have been reported. As a prolonged PRi is a fre-
quent finding associated with adverse outcomes, a better identifica-
tion of the determinants of PRi in an unselected population is
recommended. Hence, we aimed to identify the clinical determinants
of the PRi duration in the general population.
2 | METHODS
2.1 | Study Cohort
The design of the CoLaus study with the detailed baseline and follow-
up methodologies has been reported previously.13,14 Briefly, CoLaus is
a population-based prospective study exploring the biological and clini-
cal determinants of cardiovascular diseases. A non-stratified, represen-
tative sample of the population of Lausanne (Switzerland) was recruited
between 2003 and 2006, including 6733 participants according to two
inclusion criteria: (a) age 35-75 years, (b) written informed consent. The
first follow-up occurred between 2009 and 2012 and the second
between 2014 and 2017. In this cross-sectional study, all data were
collected during the second follow-up by trained field interviewers and
were obtained by a questionnaire, an interview, and a physical examina-
tion including blood tests and a 12-lead digital ECG recording.
2.2 | Electrocardiography
ECGs were digitally recorded in a resting supine position using a single
device (Cardiovit MS-2015, Schiller AG, Baar, Switzerland). In
accordance with the local standards, paper speed was 25 mm/second
and calibration 10 mV/mm. Digital ECGs were stored in an
anonymised database of SEMA Data Management System (V3.5,
Schiller AG, Baar, Switzerland).
ECG measurements were determined by Schiller AG algorithms. As
automated measurements of ECG intervals significantly vary between
manufacturers15 and the diagnostic accuracy of common ECG algo-
rithms is lower than that of cardiologists,16 100 randomly selected
ECGs were manually analyzed by M.B. The PRi was defined as the time
interval between the earliest detection of atrial depolarization and the
earliest detection of ventricular depolarization in any lead. Measure-
ments were performed at a paper speed of 100 mm/second. In case of
a > 10 ms disagreement between the automated and the manual values
or when diagnoses relative to the PRi (eg, sinus rhythm, AF) were dis-
cordant, a senior cardiologist (J.S.) reanalyzed the ECG and measured
the PRi. This procedure showed a good agreement between the PRi
durations assessed digitally and manually, except for the three following
conditions: (a) extreme digital PRi durations (>2 or < 2 SD, respectively
>220 ms or < 116 ms); (b) non sinus rhythm or AV conduction abnor-
mality; and (c) missing of PRi duration in presence of sinus rhythm.
Hence, in this study, manual analyzes were performed for these three
conditions (corresponding to 475 ECGs, ie, 13% of the ECGs). The ana-
lyzes were conducted by two investigators (M.B., F.B.) and further con-
firmed by two senior cardiologists (J.S., E.P.). For the remaining ECGs,
digitally determined PRi durations were used. PRis were then catego-
rized into prolonged (>200 ms) or normal (≤200 ms) for analysis.
2.3 | Clinical data
Age was categorized in four 10-year groups (45-54 years,
55-64 years, 65-74 years and > 75 years).
Body weight and height were measured with participants bare-
foot and in light indoor clothes. Body weight was measured to the
nearest 100 g using a Seca scale (Hamburg, Germany) and height was
measured to the nearest millimeter using a Seca height gage. Obesity
was defined as a body mass index (BMI) ≥30 kg/m2 and overweight as
BMI ≥25 kg/m2 and < 30 kg/m2. Waist circumference was measured
midway between the lowest rib and the iliac crest using a non-
stretchable tape and the average of two measurements was taken.
Abdominal obesity was defined as a waist circumference ≥ 102 cm
(men) and ≥ 88 cm (women).17
Alcohol consumption and smoking status were assessed by self-
filled questionnaire. Excessive alcohol consumption was defined as
>40 g/day for men and > 20 g/day for women.18 Participants were
considered as current or former smokers when reporting smoking
(any type of tobacco combustion), and nonsmoking otherwise.
Cardiovascular risk assessment was evaluated with two risk equa-
tions, the European Society of Cardiology SCORE19 recalibrated for
Switzerland20 and the IAS-arbeitsgruppe lipide und atherosklerose
(AGLA) score.21 The SCORE risk estimates the 10-year risk of death
from vascular causes and the AGLA risk estimates the 10-year risk of
nonfatal myocardial infarction.
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Resting heart rate was obtained on the ECG and defined as high
when ≥70 beats per minute.22 Blood pressure (BP) was measured
after at least a 10-minute rest in a seated position using an Omron
HEM-907 automated oscillometric sphygmomanometer with an
appropriately sized cuff. Three measurements separated by
10-minute intervals were performed and the average of the last two
measurements was used. Hypertension was defined by a systolic BP
≥140 mmHg and/or a diastolic BP ≥90 mmHg and/or presence of
antihypertensive treatment.
History of cardiovascular disease (CVD) included myocardial
infarction, angina pectoris, percutaneous revascularization or bypass
grafting, stroke or transient ischemic attack. History of CVD was
obtained either based on patient's report (for some of the events
occurring before the baseline CoLaus survey) or based on clinical data
(obtained during follow-up) validated by an independent adjudication
committee including cardiologists and a neurologist.14
Participants listed their medications in the self-filled question-
naire. Antiarrhythmic drugs including digoxin, calcium channel
blockers (CCBs), amiodarone, and beta-blockers were selected for
adjustment because of their impact on the PRi.
2.4 | Biological data
Fasting venous blood samples were processed in the Lausanne Univer-
sity Hospital laboratory. Biological parameters included glucose;
HbA1c; total, HDL and LDL-cholesterol; triglycerides; creatinine; NT-
proBNP; high-sensitivity cardiac troponin T (hs cTnT), and electrolytes
(magnesium, potassium, calcium) for their effect on cardiac conduction.
Diabetes mellitus was defined as fasting plasma glucose
≥7.0 mmoL/L and/or HbA1c ≥48 mmol/mol (≥6.5%) and/or anti-
diabetic treatment. Renal failure was defined by eGFR <60 mL/
min/1.73 m2 (1 mL/s/m2) using the CKD-EPI formula. Dyslipidemia
was defined either by using the LDL-cholesterol thresholds adapted
from the Systematic Coronary Risk Evaluation (SCORE) risk charts
(Table S1), and/or by presence of a lipid lowering treatment. Elevated
NT-proBNP was considered when ≥125 ng/L and elevated hs cTnT
when ≥14 ng/L (≥0.014 μg/L).
2.5 | Exclusion criteria
Exclusion criteria for the current analyzes were as follows:
(a) uninterpretable ECG (ie, unstable baseline, missing or inverted elec-
trodes); (b) no sinus rhythm or paced rhythm; (c) Wolff-Parkinson-
White syndrome or ≥ second degree AV block; and (d) missing pheno-
typic data (Figure 1).
2.6 | Statistical analyzes
Statistical analyzes were conducted using STATA version 15.1 for
Windows (Stata Corp, College Station, Texas). Concordance between
automatic and manual PRi measurements was assessed by Spearman
correlation and Lin's concordance coefficients.
Bivariate analysis of the factors associated with prolonged PRi
was performed using chi-square for qualitative variables and Student's
t-test for continuous variables. Results were expressed as number of
participants (percentage) or as average ± SD. Multivariable analysis
using the PRi duration as dependent variable was performed by step-
wise forward logistic regression and findings were further confirmed
by stepwise backward logistic regression. Results were expressed as
odds ratio (OR) and 95% confidence interval (CI).
Model 1 tested the following covariates: sex; age (45-54, 55-64,
65-74, 75+ years); height (continuous); BMI (normal, overweight,
obese); waist (normal, elevated); alcohol intake (none, moderate, exces-
sive); smoking status (never, former, current); 10-year risk of coronary
heart disease (CHD) (SCORE and AGLA: low, middle, high, very high);
diabetes mellitus (yes/no); hypertension (yes/no); dyslipidemia
(yes/no); renal insufficiency (yes/no); resting heart rate (<70, ≥70 bpm);
hs cTnT (<14, ≥14 ng/L) and NT-proBNP (<125, ≥125 ng/L). Model
2 tested the same set of variables as model 1, but adjusting for antiar-
rhythmic drugs; electrolytes (magnesium, potassium, calcium); P-wave
contribution to the length of the PRi (P duration/PR duration×100 as
suggested by Soliman and et al.23) and history of CVD. Model
3 included the same covariates as model 2, but participants under
beta-blockers and non-cardioselective CCBs (ATC C08C, C08E, and
C08G) were excluded.
Sensitivity analyzes were conducted using inverse probability
weighting. Briefly, a logistic model was built including variables signifi-
cantly different between included and excluded participants, and the
probability of inclusion was computed.24 The inverse of the probabil-
ity that the observation is included was then used as weight in the dif-
ferent models described above. A second sensitivity analysis was
conducted using age and heart rate as continuous variables. Statistical
significance was defined by a two-sided P-value <.05.
F IGURE 1 Flow diagram: participants selection procedure. AV,
atrioventricular; WPW, Wolff-Parkinson-White
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2.7 | Ethical statement and consent
The local Institutional Ethics Committee approved the baseline CoL-
aus study (reference 16/03, decisions of 13 January and 10 February
2003); the approval was renewed for the first (reference 33/09, deci-
sion of 23 February 2009) and the second (reference 26/14, decision
of 11 March 2014) follow-up. The study was performed in agreement
with the Helsinki declaration and the applicable Swiss legislation. All
participants gave their signed informed consent before entering the
study.
3 | RESULTS
3.1 | Concordance between computerized and
manual ECG analyzes
Spearman's rho was 0.95 and concordance correlation coefficient
0.95 (both P < .001). The digital algorithm related to the PRi was
incorrect for two ECGs: (a) the digital diagnosis was sinus rhythm with
an extremely long PRi, while the correct manual diagnosis was AF;
(b) the digital diagnosis was an irregular rhythm with no P-wave
detected, while the correct manual diagnosis was sinus rhythm. Fur-
thermore, P-wave and PR values were missing in a correctly diag-
nosed case of sinus bradycardia.
3.2 | Study population
Of the initial 4881 participants, 1226 (25.1%) were excluded. The rea-
sons for exclusion are shown in Figure 1 and the characteristics of
excluded and included participants are summarized in Table S2.
Excluded participants were older, shorter, with higher BMI, had more
abdominal obesity, excessive alcohol intake, diabetes, renal insuffi-
ciency, elevated CHD risk scores, dyslipidemia, hypertension, high
resting heart rate and elevated hs cTnT and NT-proBNP than
included ones.
3.3 | Factors associated with prolonged PRi
Of the 3655 participants with interpretable ECG and measurable PRi
duration, 330 (9.0%, 95% CI 8.1 to 10.0%) presented with a prolonged
PRi. The clinical characteristics of the participants, overall and
according to categories of PRi duration, are presented in Table 1. Par-
ticipants with prolonged PRi were more frequently male, old, tall and
obese. They also had a higher prevalence of renal failure, dyslipidemia,
elevated CHD risk scores, hypertension and elevated hs cTnT and
NT-proBNP levels. Inversely, they were less prone to smoke and to
have high resting heart rate.
Table 2 displays the results of the multivariable stepwise logistic
regression assessing the associations between prolonged PRi and clin-
ical characteristics. In model 1, male sex, older age, increased height,
hypertension and elevated hs cTnT were significantly and positively
associated with prolonged PRi, while high resting heart rate was nega-
tively associated.
After further adjustment according to model 2, male sex, older
age, and increased height remained positively, and high resting heart
rate negatively associated with prolonged PRi. Conversely, hyperten-
sion and hs cTnT were no longer associated. Results were similar after
exclusion of participants under beta-blockers and non-cardioselective
CCBs (model 3).
3.4 | Sensitivity analysis
The results of the sensitivity analysis using inverse probability
weighting are summarized in Table S3. The factors retained were
identical to those of the initial analyzes. Similar findings were obtained
using age and heart rate as continuous variables (Table S4).
4 | DISCUSSION
In this study, male sex, older age and increased height were signifi-
cantly and positively associated with prolonged (>200 ms) PRi, while
high resting heart rate was negatively associated. These associations
were independent of the P-wave contribution to the length of PRi.
4.1 | Agreement between computerized and
manual ECG analyzes
The concordance between manual and digital measures of PRi dura-
tion and PRi-related diagnoses was good. It has been demonstrated
that errors in digital ECG diagnoses are frequently related to arrhyth-
mia and conduction disorders.16 In our study, there were two incor-
rect ECG diagnoses by the digital algorithm: one sinus rhythm case
misdiagnosed as AF, and one AF case misdiagnosed as an extremely
long PRi. In summary, our ECG digital data were reliable for epidemio-
logical studies, but a validation of the algorithm on ECGs sample, and
a manual reading is recommended for the following conditions:
(a) extreme digital PRi durations (> or < 2 SD); (b) non sinus rhythm or
AV conduction abnormality; and (c) absence of PRi duration when
sinus rhythm is reported.
4.2 | Prevalence of prolonged PRi
In our sample, approximately one out of 11 (9.0%, 95% CI 8.1-10.0)
participants had a prolonged PRi. This is in mid-range of other studies
reporting prevalence rates ranging from 1.6% to 18%.6,7,9,11,23 Several
explanations may help to explain these differences. First, by the differ-
ent characteristics of the studied populations; for example, Holmqvist
et al.11 reported an 18% prevalence rate of prolonged PRi but partici-
pants with established coronary artery disease were included, a
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condition known to increase the risk of prolonged PRi. Second, by dif-
ferent age; Cheng et al.6 reported a low (1.6%) prevalence rate in a
sample with a mean age of 47 years compared to >60 years in the
present study. Conversely, a study reporting prevalence rate of pro-
longed PRi in a population similar to CoLaus showed a comparable
result (8.7%).23
TABLE 1 Clinical characteristics of the participants, overall and according to PR interval duration, CoLaus/PsyCoLaus study, Lausanne,
Switzerland, 2014-2017
Overall PR ≤ 200 ms PR > 200 ms P-value
No. 3655 3325 330
Female sex (%) 2032 (55.6) 1900 (57.1) 132 (40.0) <.001
Age (y) 61.8 ± 9.9 61.3 ± 9.7 66.6 ± 10.6 <.001
Age categories (y) (%) <.001
45–54 1096 (29.9) 1035 (31.1) 61 (18.5)
55–64 1201 (32.9) 1128 (33.9) 73 (21.1)
65–74 944 (25.8) 834 (25.1) 110 (33.3)
75+ 414 (11.3) 328 (9.9) 86 (26.1)
Height (cm) 167.8 ± 9.5 167.5 ± 9.4 170.1 ± 10.3 <.001
Body mass index (kg/m2) 26.2 ± 4.6 26.2 ± 4.7 26.8 ± 4.1 .02
Body mass index categories .03
Normal 1572 (43.0) 1452 (43.7) 120 (36.4)
Overweight 1445 (39.5) 1302 (39.2) 143 (43.3)
Obese 638 (17.5) 571 (17.2) 67 (20.3)
Abdominal obesity (%) 1310 (35.8) 1176 (35.4) 134 (40.6) .06
Alcohol intake (%) .34
None 951 (26.0) 858 (25.8) 93 (28.2)
Moderate 2492 (68.2) 2269 (68.2) 223 (67.6)
Excessive 212 (5.8) 198 (5.9) 14 (4.2)
Smoking (%) .009
Never 1546 (42.3) 1396 (41.9) 150 (45.5)
Former 1426 (39.0) 1287 (38.7) 139 (42.1)
Current 683 (18.7) 642 (19.3) 41 (12.4)
Diabetes mellitus (%) 334 (9.1) 295 (8.9) 39 (11.8) .08
Renal failure (%) 291 (7.9) 247 (7.4) 44 (13.3) <.001
10 year risk of CHD (SCORE) <.001
Low <1% 1124 (30.8) 1066 (32.1) 58 (17.6)
Medium (≥1 to <5%) 1397 (38.2) 1281 (38.5) 116 (35.2)
High (≥5 to <10%) 698 (19.1) 599 (18.0) 99 (30.0)
Very high (≥10%) 436 (11.9) 379 (11.4) 57 (17.3)
Dyslipidemia (SCORE) (%) 1588 (43.5) 1404 (42.2) 184 (55.8) <.001
10 year risk of CHD (AGLA) <.001
Low (<10%) 2582 (70.6) 2385 (71.7) 197 (59.7)
Middle (10-19%) 142 (3.9) 124 (3.7) 18 (5.5)
High (≥20%) 83 (2.3) 69 (2.1) 14 (4.2)
Very high 848 (23.2) 747 (22.5) 101 (30.6)
Hypertension (%) 1588 (43.5) 1393 (41.9) 195 (59.1) <.001
Elevated (≥70 bpm) resting heart rate (%) 650 (17.8) 617 (18.6) 33 (10.0) <.001
Elevated (≥14 ng/L) hs cTnT (%) 236 (6.5) 181 (5.4) 55 (16.7) <.001
Elevated (≥125 ng/L) NT-proBNP (%) 744 (20.4) 639 (19.2) 105 (31.8) <.001
Note: Results are expressed as mean ± SD or as number of participants (percentage). Between-group comparisons using chi-square or student t test.
Abbreviations: AGLA, Arbeitsgruppe Lipide und Atherosklerose; bpm, beats per minute; CHD, coronary heart disease; hs cTnT, high-sensitivity cardiac
troponin T.
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4.3 | Factors associated with prolonged PRi
Older age was positively associated with prolonged PRi, participants
aged >75 years having a more than fourfold increase in the likelihood
of prolonged PRi compared to the youngest age category. Similar find-
ings were obtained when age was used as a continuous variable. This
is a consistent finding in the literature.7,10,11 A major explanation is
that fibrosis increases in the aging heart due to inflammation,
haemodynamic factors, cellular senescence and death, and reactive
oxygen species25 and, subsequently, increased fibrosis slows cardiac
conduction leading to prolonged PRi.26
Male sex was positively associated with prolonged PRi, a finding
also reported elsewhere.7,11 The reasons for this association are not
completely understood. It has been proposed that men have a larger
heart size, implicating a longer His-Purkinje system and hence a pro-
longed conduction time.27 Sex hormones might also be implicated: an
animal study has demonstrated that estrogen attenuates the pro-
myofibroblast proliferation effect of angiotensin II,28 thus reducing
cardiac fibrosis. Nevertheless, the reasons why male sex increases the
likelihood of prolonged PRi are still speculative and deserve further
investigations.
A 5 cm increase in height increased the likelihood of a prolonged
PRi by 26%. To our knowledge, height has been seldom associated
with ECG characteristics. Nonetheless, both the PRi and height have
been linked with AF,6,29 and Kofler et al.30 recently observed signifi-
cant associations of measured and genetically determined height with
PRi suggesting that “adult height is a marker of altered cardiac con-
duction and that these relationships might be causal.”30 Our results
support this hypothesis. However, the commonly advanced explana-
tion that tall persons also have a larger heart, which causes PRi pro-
longation is now debated.30
High resting heart rate was the only factor associated with a
reduced likelihood of a prolonged PRi, a finding also reported else-
where.7 A plausible explanation is that sympathetic activity increases
heart rate by shortening the cardiac conduction cycle, partly by accel-
erating the AV node conduction.31
Hypertension and elevated hs cTnT were positively but inconsis-
tently associated with prolonged PRi. A possible explanation for
hypertension not being retained in model 2 is linked to the adjust-
ment for medication. As hypertension was defined partly by the
presence of antihypertensive drugs (beta-blockers and CCBs
included), adjusting for antihypertensive drugs reduced the strength
TABLE 2 Multivariable associations between prolonged (>200 msec) PR interval and clinical characteristics of participants, CoLaus/
PsyCoLaus study, Lausanne, Switzerland, 2014-2017
Model 1 (n = 3655) Model 2 (n = 3397) Model 3 (n = 2991)
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Sex
Female 1 (ref.) 1 (ref.) 1 (ref.)
Male 1.41 (1.02-1.97) .040 1.78 (1.20-2.66) .005 2.14 (1.36-3.35) .001
Age (y)
45-54 1 (ref.) 1 (ref.) 1 (ref.)
55-64 1.11 (0.77-1.58) .582 1.21 (0.80-1.82) .368 1.17 (0.76-1.82) .47
65-74 2.29 (1.61-3.24) <.001 2.42 (1.60-3.68) <.001 2.67 (1.70-4.19) <.001
75+ 4.21 (2.81-6.31) <.001 5.12 (3.19-8.21) <.001 5.39 (3.16-9.21) <.001
P-value for trend <.001 <.001 <.001
Height (per 5 cm) 1.15 (1.06-1.25) .001 1.23 (1.12-1.37) <.001 1.26 (1.12-1.42) <.001
Hypertension
No 1 (ref.) Not retained Not retained
Yes 1.37 (1.06–1.77) .015
Resting heart rate
Normal (<70 bpm) 1 (ref.) 1 (ref.) 1 (ref.)
Elevated (≥70 bpm) 0.43 (0.29-0.62) <.001 0.54 (0.34-0.85) .007 0.44 (0.25-0.77) .004
Hs cTnT categories
Normal (<14 ng/L) 1 (ref.) Not retained Not retained
Elevated (≥14 ng/L) 1.67 (1.15-2.43) .007
Note: Results are expressed as multivariable-adjusted odds ratio (95% confidence interval). Analysis by stepwise forward logistic regression; results were
further confirmed by stepwise backward logistic regression. Model 1 included all variables from Table 1 except for age and BMI as continuous variables.
Model 2 tested the same set of variables as model 1, but adjusting for antiarrhythmic drugs; electrolytes (magnesium, potassium, calcium); P-wave
contribution to the length of the PR interval (P duration/PR duration×100) and history of CVD. Model 3 included the same covariates as in model 2, but
participants under beta-blockers and non-cardioselective CCBs were excluded.
Abbreviations: bpm, beats per minute; CI, confidence interval; Hs cTnT, high-sensitivity cardiac troponin T, OR, odds ratio .
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of the association. Still, hypertension was not retained even after
excluding participants on beta-blockers and non-cardioselective
CCBs. This echoes the contradictory findings of the literature, where
significant11 or non-significant7,9 associations between hypertension
and PRi duration have been reported. Similarly, hs cTnT was incon-
sistently associated with PRi duration, possibly because of the
adjustment for CVD history. Yet, and despite the inconsistent statis-
tical findings, we believe that hypertension and hs cTnT might be
associated with prolonged PRi as both increase the risk of cardiac
fibrosis.25,32
4.4 | Limitations
This study has several limitations. First, it was limited to an age range
of 45 to 86, and might not be applicable in younger or older partici-
pants. Second, the sample was mostly restricted to Caucasians and
might not be generalizable to other ethnicities. Third, a sizable frac-
tion (one-quarter) of the sample was excluded, and excluded partici-
pants differed from the included ones regarding the levels of several
determinants of prolonged PRi; this might have biased the associa-
tions between potential determinants and prolonged PRi. Still, the
results obtained were almost identical when inverse probability
weighting was applied. Finally, most PRi durations were digitally
measured and errors may have occurred. However, we endeavored
to control the reliability of the digital analyzes and optimize the man-
ual reading.
4.5 | Conclusion
In a sample of the Swiss middle-aged population, male sex, older age,
and increased height significantly increased the likelihood of a pro-
longed PRi duration, whereas high resting heart rate decreased it. The
effect of hypertension and elevated hs cTnT on the PRi duration
needs further investigations.
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